Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs GeneDx Holdings Corp — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.84 (market cap $135.69M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 14.9× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 61 Days and GeneDx Holdings Corp for 19 Days on average.
| GPTY | WGS | |
|---|---|---|
Market Cap | $135.69M | $2.02B |
Volume | 97,442 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $167.51 |
52-Week Low | $34.73 | $34.51 |
Typical Hold Time | 61 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $42.84, down 0.76% with a bullish technical outlook from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.29-0.30, providing income generation. Recent coverage highlights the fund's AI-focused covered call strategy as offering high yield potential while retaining some upside participation in tech rallies.
The outlook remains positive for income-seeking investors, with the options-based strategy generating substantial distributions. Key risks include market volatility impacting the underlying AI portfolio and the trade-off between income generation and capital appreciation potential in strong bull markets.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
